Abstract: The present invention provides engineered T7 RNA polymerase variants and compositions thereof. These variants have been evolved for selective incorporation of the symmetrical capped GTP analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for using the variants provided herein. The present invention further provides for the use of the compositions provided herein.

Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).

Abstract: The present invention relates to variants of a parent glucoamylase having altered properties (e.g., improved thermostability and/or specific activity). In particular, the present invention provides compositions comprising the variant glucoamylases, including starch hydrolyzing compositions, animal feed compositions and cleaning compositions. The invention also relates to DNA constructs encoding the variants and methods of producing the glucoamylase variants in host cells.

Abstract: Described are methods and compositions relating to granular starch-converting glucoamylases and ?-amylases. The enzymes can be used to perform enzymatic starch hydrolysis of granular starch at or below the gelatinization temperature of insoluble granular starch.

Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: Polynucleotide sequences are provided encoding a thermostable cellulase and directing its increased expression are provided, and the use of the thermostable cellulase in hydraulic fracturing methods and the treatment of flowback fluids.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.

Abstract: The application relates to a polypeptide having beta-glucosidase activity, its method of production and its uses.

Abstract: The application relates to a polypeptide having beta-glucosidase activity, its method of production and its uses.

Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: Disclosed are isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. Nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides are also disclosed.

Abstract: The invention is in the field of protein chemistry, in particular in the field of enzymology. It provides pectinases, i.e. polypeptides with pectin-degrading properties. In particular the invention provides polypeptides with pectate lyase activity (EC 4.2.2.2). Enzymes according to the invention have improved properties, such as improved thermostability and decreased calcium dependence.

Abstract: The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3? end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein.

Abstract: An embodiment of the present disclosure provides an apparatus for immobilizing a microbial cell, the apparatus including: a mixing tank in which a cell-carrier-containing mixed solution is accommodated; a nozzle part through which the cell-carrier-containing mixed solution is injected from the mixing tank and is discharged to the outside; and a reaction tank in which a cell immobilized bead is formed by contact between the cell-carrier-containing mixed solution discharged from the nozzle part and an aqueous curing agent solution. In the apparatus for immobilizing a microbial cell according to the present disclosure, since the cell-carrier-containing mixed solution is injected through an air spraying nozzle, even when an immobilized carrier solution having a high viscosity is used, a microbial cell immobilized bead having a small size and having a spherical shape, or an almost spherical shape may be mass-produced.

Abstract: In one embodiment, the present invention relates to a non-enzymatic method for isolating stem cells from adipose tissue, wherein the method comprises treating adipose tissue with ultrasonic cavitation to break up the adipose tissue and lyses mature adipocytes, resulting in a stromal vascular fraction containing viable stromal/stem cells.

Abstract: Disclosed herein, among other things, are methods, kits and compositions that include a thermostable Argonaute protein and a thermostable single-stranded DNA binding protein (SSB).

Abstract: The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for delivering such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.

Abstract: A method of extracting DNA and/or RNA from a cell or capsid, the method comprising steps of: (a) contacting a composition comprising the cell or capsid with a composition comprising (ii) a quaternary ammonium compound or a precursor thereof; and (b) contacting the composition obtained in step (a) with a composition comprising a proteinaceous washing agent.

Abstract: The present invention relates to monodisperse silanized ferrimagnetic iron oxide particles, a method for producing the same and a method for independent generic binding of nucleic acid molecules to the particles.

Abstract: Provided are methods for preparing a library of target nucleic acid sequences, as well as compositions and uses therefor. Methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting the resulting first amplification products; repairing the digested target amplicons; and amplifying the repaired products in a second amplification, thereby producing a library of target nucleic acid sequence. Each of the plurality of adaptor compositions comprise a handle and a targeted nucleic acid sequence and optionally one or more tag sequences. Provided methods may be carried out in a single, addition only workflow reaction, allowing for rapid production of highly multiplexed targeted libraries, optionally including unique tag sequences. Resulting library compositions are useful for a variety of applications, including sequencing applications.

Abstract: The present invention relates to compositions involving randomized in-frame fusion polynucleotides and their introduction into a host organism to identify desirable phenotypic changes. The present invention further relates to methods of generating these randomized in-frame fusion polynucleotides by introducing randomized in-frame fusion polynucleotides into an organism, selecting for organisms with new or altered phenotypes, re-isolating the randomized in-frame fusion polynucleotides from the selected organisms, re-assembling the constituent polynucleotides of the re-isolated randomized in-frame fusion polynucleotides into new collections of randomized in-frame fusion polynucleotides, and repeating the selection for organisms with new or altered phenotypes.

Abstract: In an illustrative embodiment, cell libraries created by rationally designed nucleic acids comprising sequences to facilitate nuclease-directed genome editing events are provided. The cell libraries include saturation mutagenesis cell libraries, promoter swap cell libraries, SNP swap cell libraries, terminator swap cell libraries, and combinations thereof.

Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid.

Abstract: Described are compounds and methods useful for the treatment and investigation of Friedreich's Ataxia.

Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).

Abstract: An isolated dsRNA molecule comprising an antisense RNA sequence for regulating a target gene of interest in a plant or a phytopathogen of the plant, wherein the dsRNA sequence is flanked by two complementary sites to an smRNA or smRNAs expressed in the plant and wherein the dsRNA molecule further comprises a helicase binding site positioned so as to allow unwinding of the strands of the isolated dsRNA molecule to single stranded RNA (ssRNA) and recruitment of an RNA-dependent RNA polymerase so as to amplify the dsRNA molecule in the plant cell and generate secondary siRNA products of the dsRNA sequence.

Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.

Abstract: The present invention relates to a novel, RNAi-inducing nucleic acid molecule having cell penetrating ability and the use thereof, and more particularly, to a novel, RNAi-inducing double-stranded nucleic acid molecule, which has a replacement of the phosphate backbone of at least one nucleotide with phosphorothioate or phosphorodithioate, and has a lipophilic compound conjugated thereto, and thus has high target gene-silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle, and to a method of silencing a target gene using the nucleic acid molecule. The nucleic acid structure according to the present invention has both cholesterol modification and phosphorothioate modification introduced therein, and thus has high gene silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle.

Abstract: Provided herein is a molecular robot comprising (v) a molecular motor composed of a first nucleic acid scaffold and a functional core with a catalytic center of an ATP-driven motor embedded therein; (vi) an ion channel; (vii) a hollow drillhead composed of a second nucleic acid scaffold; and (viii) at least two rods, wherein each rod is composed of a third nucleic acid scaffold and at least one aptamer on its distal end, and wherein each rod is connected to the molecular motor via its proximal end.

Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.

Abstract: Methods of treating cancer using antisense based therapies including antisense oligonucleotides of si RNAs directed against DNA double-strand break repair proteins such as BRCA2 or RAD51 are provided. The antisense based therapies can be used alone, in tandem or in combination with other cancer therapies, in particular with therapies that lead to DNA damage, inhibition of DNA repair or inhibition of DNA synthesis, such as radiation, platinum drugs, alkylating agents, PARP inhibitors, or inhibitors of thymidylate synthase.

Abstract: The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.

Abstract: Described herein are methods, compounds, pharmaceutical compositions, and kits for modulating erythropoiesis by altering occupancy at genomic signaling-centers.

Abstract: Provided herein are methods for decreasing Ataxin-2 mRNA expression. Such methods are useful to ameliorate symptoms of Ataxin-2 associated diseases. Such Ataxin-2 associated diseases include amyotrophic lateral sclerosis (ALS). Such symptoms include loss of motor function, reduced compound muscle action potential (CMAP) amplitude, denervation, and loss of motor neurons. Specifically, the methods comprising administering to an animal having ALS an oligomenc compound comprising a modified oligonucleotide, wherein the modified oligonucleotide has a nucleobase sequence that is complementary to an Ataxin-2 nucleic acid.

Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid.

Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.

Abstract: This disclosure provides compositions, including Listeria delivery vectors comprising minigene expression constructs, and methods of using the same for inducing an immune response against an antigen-expressing tumor and for treating the same, and vaccinating against the same in subjects bearing the tumors.

Abstract: The present disclosure includes methods and components for production of valuable industrial compounds in yeast. In an embodiment, the present invention provides a nucleic acid construct with increased stability for gene expression or gene editing comprising: a nucleic acid sequence encoding one or more of SEQ ID NO: 1-8 (CENs 1-8); and one or more regulatory elements functional in a yeast cell. In an embodiment of the present invention the nucleic acid constructs are vectors, preferably episomal vectors. High expression promoters, as well as methods for increasing production of compounds such as aromatics are disclosed.

Abstract: Strains of yeast genetically engineered to produce increased amounts of non-hydroxylated collagen or hydroxylated collagen are described. An all-in-one vector including the DNA necessary to produce collagen, promotors, and hydroxylating enzymes is also described. Methods for producing non-hydroxylated or hydroxylated collagen are also provided.

Abstract: The invention relates to the soybean variety designated 01068085. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01068085. Also provided by the invention are tissue cultures of the soybean variety 01068085 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01068085 with itself or another soybean variety and plants produced by such methods.

Abstract: The invention relates to the soybean variety designated 01068083. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01068083. Also provided by the invention are tissue cultures of the soybean variety 01068083 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01068083 with itself or another soybean variety and plants produced by such methods.

Abstract: The invention relates to the soybean variety designated 01068084. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01068084. Also provided by the invention are tissue cultures of the soybean variety 01068084 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01068084 with itself or another soybean variety and plants produced by such methods.

Abstract: The invention relates to the soybean variety designated 01064280. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01064280. Also provided by the invention are tissue cultures of the soybean variety 01064280 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01064280 with itself or another soybean variety and plants produced by such methods.

Abstract: The invention relates to the soybean variety designated 01068088. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01068088. Also provided by the invention are tissue cultures of the soybean variety 01068088 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01068088 with itself or another soybean variety and plants produced by such methods.

Abstract: The invention relates to the soybean variety designated 01068093. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01068093. Also provided by the invention are tissue cultures of the soybean variety 01068093 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01068093 with itself or another soybean variety and plants produced by such methods.

Abstract: The invention relates to the soybean variety designated 01064519. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01064519. Also provided by the invention are tissue cultures of the soybean variety 01064519 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01064519 with itself or another soybean variety and plants produced by such methods.